C3 International Inc.

The Mission of C3® International, Inc. is to manufacture the unique Intellectual Property for Idrasil™; A disruptive advancement in the standardization and titration for Hepatic delivery of natural, whole and active Cannabinoids, in a divisible tablet that is Rx only & major Insurance Reimbursable, for Quality of Life (QoL).

OVERVIEW
IdrasilTM (Cannabis) 12.5mg, 25mg, 100mg tablets, provide all of the medicinal analgesic
& therapeutic benefits of medical cannabis in pill form.
By ingesting the compound more of the therapeutic benefits are obtained than when inhaled and unwanted euphoria is eliminated.
Our proprietary process isolates all of the cannabinoids from the cloned cannabis plant, resulting in pure natural extraction Our pharmaceutical grade manufacturing
process is FDA Complaint, Sterile, GMP, ISO 9000 and GRAS.
 
MARKET SIZE
IdrasilTM provides relief for patients struggling with endocannabinoid deficiencies (ECD).
The global patient population for ECD is estimated to be as high as 1.1 billion.